Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Pivekimab sunirine plus venetoclax and azacitidine in unfit patients with newly diagnosed AML

Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents results from a Phase Ib/II study (NCT04086264) of pivekimab sunirine, a CD123-targeting antibody-drug conjugate, plus venetoclax and azacitidine in unfit patients with newly diagnosed acute myeloid leukemia (AML). He highlights a robust complete remission rate, particularly in TP53 wild-type disease, a manageable safety profile, and mentions the ongoing randomized Phase II/III REVIVAL trial (NCT07581002). This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) 2026, held in Cambridge, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.